Mosapride structure
|
Common Name | Mosapride | ||
---|---|---|---|---|
CAS Number | 112885-41-3 | Molecular Weight | 421.893 | |
Density | 1.3±0.1 g/cm3 | Boiling Point | 549.2±50.0 °C at 760 mmHg | |
Molecular Formula | C21H25ClFN3O3 | Melting Point | 151-153°C | |
MSDS | N/A | Flash Point | 286.0±30.1 °C |
Use of MosaprideMosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhoea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000 - 3,000 times the therapeutic dose to elicit cardiovascular effects. |
Name | 4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide |
---|---|
Synonym | More Synonyms |
Description | Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.Target: 5HT4 Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist. The major active metabolite of mosapride, known as M1, additionally acts as a 5HT3 antagonist, which accelerates gastric emptying throughout the whole of the gastrointestinal tract in humans, and is used for the treatment of gastritis, gastro-oesophageal reflux disease, functional dyspepsia and irritable bowel syndrome. It is recommended to be taken on an empty stomach (i.e. at least one hour before food or two hours after food).In addition to its prokinetic properties, mosapride also exerts anti-inflammatory effects on the gastrointestinal tract which may contribute to some of its therapeutic effects. Mosapride also promotes neurogenesis in the gastrointestinal tract which may prove useful in certain bowel disorders. The neurogenesis is due to mosapride's effect on the 5-HT4 receptor where it acts as an agonist.Its common side effects include dry mouth, abdominal pain, dizziness, headache, insomnia, malaise, nausea, diarrhoea and sometimes constipation. Unlike some other prokinetic agents, mosapride has little effect on potassium channels, no effect on hERG transfected cells, and no effect on cardiovascular function that could be detected in tests on humans. Due to the pharmacokinetics of mosapride, it would take 1,000 - 3,000 times the therapeutic dose to elicit cardiovascular effects. |
---|---|
Related Catalog | |
References |
[2]. Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91. |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 549.2±50.0 °C at 760 mmHg |
Melting Point | 151-153°C |
Molecular Formula | C21H25ClFN3O3 |
Molecular Weight | 421.893 |
Flash Point | 286.0±30.1 °C |
Exact Mass | 421.156860 |
PSA | 76.82000 |
LogP | 2.82 |
Vapour Pressure | 0.0±1.5 mmHg at 25°C |
Index of Refraction | 1.585 |
Storage condition | -20°C Freezer |
Material Safety Data Sheet
Section1. Identification of the substance Product Name: Mosapride Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section3. Composition/information on ingredients. Ingredient name:Mosapride CAS number:112885-41-3 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels. Storage: Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified Boiling point:No data No data Melting point: Flash point:No data Density:No data Molecular formula:C21H25ClFN3O3 Molecular weight:421.9 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A |
Hazard Codes | C,N,F+ |
---|---|
Risk Phrases | R14:Reacts violently with water. R34:Causes burns. R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R12:Extremely Flammable. |
Safety Phrases | S26-S27-S28-S36/37/39-S45-S61-S33-S29-S16 |
RIDADR | UN 3260 8/PG 2 |
WGK Germany | 3 |
RTECS | LW9100000 |
Packaging Group | II |
Hazard Class | 8 |
HS Code | 2934999090 |
~97% Mosapride CAS#:112885-41-3 |
Literature: WO2003/106440 A2, ; Page 10 ; |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: US2012/64162 A1, ; |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
~% Mosapride CAS#:112885-41-3 |
Literature: Journal of Medicinal Chemistry, , vol. 34, # 2 p. 616 - 624 |
Precursor 9 | |
---|---|
DownStream 4 | |
HS Code | 2934999090 |
---|---|
Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Benzamide, 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]- |
4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide |
MFCD00867430 |
Mosapride |
(±)-4-Amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide |
4-Amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)-2-morpholinyl]methyl}benzamide |
4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]benzamide |
4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}benzamide |